CellaVision AB
STO:CEVI

Watchlist Manager
CellaVision AB Logo
CellaVision AB
STO:CEVI
Watchlist
Price: 217 SEK 1.17% Market Closed
Market Cap: 5.2B SEK
Have any thoughts about
CellaVision AB?
Write Note

CellaVision AB
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CellaVision AB
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
CellaVision AB
STO:CEVI
Current Portion of Long-Term Debt
kr20.4m
CAGR 3-Years
-19%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Elekta AB (publ)
STO:EKTA B
Current Portion of Long-Term Debt
kr1.3B
CAGR 3-Years
-17%
CAGR 5-Years
6%
CAGR 10-Years
N/A
S
Surgical Science Sweden AB
STO:SUS
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Getinge AB
STO:GETI B
Current Portion of Long-Term Debt
kr3.1B
CAGR 3-Years
7%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Arjo AB (publ)
STO:ARJO B
Current Portion of Long-Term Debt
kr2.3B
CAGR 3-Years
-12%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
S
Stille AB
STO:STIL
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CellaVision AB
Glance View

Market Cap
5.2B SEK
Industry
Health Care

CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.

CEVI Intrinsic Value
265.65 SEK
Undervaluation 18%
Intrinsic Value
Price

See Also

What is CellaVision AB's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
20.4m SEK

Based on the financial report for Sep 30, 2024, CellaVision AB's Current Portion of Long-Term Debt amounts to 20.4m SEK.

What is CellaVision AB's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
25%

Over the last year, the Current Portion of Long-Term Debt growth was -53%. The average annual Current Portion of Long-Term Debt growth rates for CellaVision AB have been -19% over the past three years , 25% over the past five years .

Back to Top